Monoclonal antibodyPhase 3 trialInvestigational
Olaratumab
How it works
Blocks the action of platelet-derived growth factor (PDGF), which fuels cancer cell growth and survival.
Cancer types
Efficacy
In clinical trials, around 30% of patients with metastatic castration-resistant prostate cancer achieved a significant delay in radiographic progression, with a median overall survival of approximately 15 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.